FDA inspection
Revance Therapeutics Inc: FDA inspection ending Jul 15, 2022
FDA inspection 1175262 · Voluntary Action Indicated (VAI) · Newark, CA
Key facts
| Inspection ID | 1175262 |
|---|---|
| Firm | Revance Therapeutics Inc |
| FEI number | 3007772056 |
| Address | 7555 Gateway Blvd |
| City | Newark |
| State | CA |
| ZIP | 94560-1152 |
| Fiscal year | 2022 |
| Inspection end date | Jul 15, 2022 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | New Drug Evaluation |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- Yes Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data